nav-left cat-right
cat-right

Kidney improvement sustained by Abbott drug-study

NEW YORK, June 24 (Reuters) – Diabetics with moderate to severe chronic kidney disease showed significant and sustained improvement in kidney function through 52 weeks of treatment with a novel drug being developed by Abbott Laboratories (ABT.N), according to data from a midstage clinical trial. The oral drug, bardoxolone methyl, is the first medicine to demonstrate improvement in kidney function in patients with the...

Pfizer’s Remoxy Fails to Win FDA Approval

WASHINGTON — The latest attempt at an abuse-resistant formulation of oxycodone (Remoxy) failed to win approval from the FDA, according to a statement from Pfizer. Late Thursday, the company said it had received a complete response letter from the FDA, which described the reasons for the FDA’s decision. The FDA had turned down an earlier version of the drug in 2008, but Pfizer’s King Pharmaceuticals...

New Drug Effectively Treats Hepatitis C

WEDNESDAY, June 22 (HealthDay News) — The recently approved drug Incivek, combined with two standard drugs, is highly effective at treating hepatitis C, a notoriously difficult-to-manage liver disease, two new studies show. The drug works not only in patients just starting treatment, but in those who failed earlier treatment, the research found. The hepatitis C virus can lurk in the body for years, causing liver...

UPDATE 1-Pfizer stop-smoking pill raises heart ris...

WASHINGTON, June 16 (Reuters) – Pfizer Inc’s (PFE.N) stop-smoking drug Chantix can lead to a small increase in cardiovascular problems such as heart attacks for patients who already have cardiovascular disease, U.S. drug regulators said on Thursday. The Food and Drug Administration is changing the label for Chantix after reviewing the results of a clinical trial. An independent randomized trial of 700 smokers with...

FDA Okays New HIV Drug

WASHINGTON — The FDA has approved rilpivirine (Edurant) for the treatment of HIV patients who have not yet begun therapy. The drug, a non-nucleoside reverse transcriptase inhibitor, is intended to be used as part of highly active anti-retroviral therapy (HAART) with at least two other medications, the agency said. Rilpivirine, also known as TMC278, is to be taken once a day with food and offers another medication...

Microneedle Drug Delivery Systems Moving Toward Co...

Evolutionary Design Enhancements Creating a Viable Path to the Market According to Greystone Research Associates (Amherst, NH) – For the past decade a small group of device development companies, often supported by academic partners and national government technology transfer programs, have been attempting to commercialize drug delivery products based on arrays of microneedles. By creating channels in the stratum corneum,...
Page 5 of 15« First...34567...10...Last »